



November 13, 2018

To,
BSE Limited
Department of Corporate Services,
1st Floor, P.J. Towers, Dalal Street
Mumbai — 400001

Dear Sir,

Sub: Submission of Un-audited Financial Results for the half year ended September 30, 2018 as per clause 52 of SEBI ((Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Security code : 951165 Security ID :22RMDL19, ISIN : INE959H07011
Security code : 952953 Security ID : 22RMDL19A, ISIN : INE959H07029

Pursuant to Regulation 52 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith, un-audited financial results of Relisys Medical Devices Limited for the half year ended on September 30, 2018 along with the information required under Regulation 52 (4). The un-audited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on November 13, 2018. The Limited Review Report on the un-audited financial results, issued by the Statutory Auditors of the Company is also enclosed. Further in respect of the same please find enclosed the following information:-

Rs. In Lakhs

Credit rating in respect of NCD	:	CRISLB-/Stable
Debt-equity ratio	:	1.23
Net worth	:	Rs. 2850.11
Debt Service Coverage Ratio	:	1.12
Interest Service Coverage Ratio	:	1.12
Debenture Redemption Reserve	:	Rs. 1,450.00
Net profit/loss after tax	:	Rs. 81.35
Earnings per share	:	0.28

Start Time of the Board Meeting : 10 : 00 AM
End Time of the Board Meeting : 02: 00 PM

Yours faithfully,
For Relisys Medical Devices Limited

Dr. N. Krishna Reddy
Chairman and Managing Director
DIN: 00910584



RELISYS MEDICAL DEVICES LIMITED



November 13, 2018

To,
Listing Compliance Department,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai — 400 001.

Dear Sir/Madam,

Subject: Submission of Statement of Material Deviations as per the Regulation 52(7) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to the Regulation 52(7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby state that there is no material deviations in use of proceeds of issue of Non-Convertible Debt securities from the objects stated in the offer document for the Half Year ended September 30, 2018.

Kindly take the same on record and acknowledge.

Thanking you,

Yours truly,

For Relisys Medical Devices Limited

Dr. N. Krishna Reddy
Chairman and Managing Director
DIN: 00910584



RELISYS MEDICAL DEVICES LIMITED

Relisys Medical Devices Limited
CIN: U85101TG1997PLC028153

Regd. Office: Sy No.312, Pocharam Road, Mangalapally Village, Ibrahimpatnam, Telangana 501510 India

Statement of Unaudited Financial Results for the half year ended 30th Sept 2018

INR in Lakhs

Particulars	for the half year ended 30 September, 2018	for the half year ended 30 September, 2017
Revenue		
Revenue from operations	2,222.25	1,852.30
Other income	125.26	31.21
Total Revenue	2,347.51	1,883.51
Expenses		
Cost of materials consumed	259.77	198.77
Purchase of traded goods	-	3.60
Changes in inventories of finished goods and work-in-progress	(90.06)	4.42
Employee benefits expense	311.64	267.04
Finance Cost	675.75	87.29
Depreciation and amortization expense	148.70	169.28
Other expenses	957.75	758.97
Total Expenses	2,264	1,489
Profit / (Loss) before tax	83.96	394.14
Tax expense:		
Current tax (Minimum Alternative tax Credit)	29.00	-
Less: Minimum Alternative tax Credit	(26.39)	-
Deferred tax	-	-
Profit / (Loss) for the year	81.35	394.14
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Re-measurement gains/(losses) on defined benefit plans	(5.50)	(1.94)
Tax on items that will not be reclassified to profit or loss	-	-
Total Other comprehensive loss for the year, net of tax	(5.50)	(1.94)
Total comprehensive income for the year, net of tax	75.85	392.20

Particulars	As at 30 September, 2018	As at 30 September, 2017
Paid up Equity Share Capital (3,42,50,523 (2018: 3,44,70,181) Equity shares of Rs. 10 each)	3,427.05	2,759.61
Reserves (excluding Revaluation Reserve)	(576.95)	(3,411.37)
Net worth	2,850.11	(651.75)
Paid up debt Capital / Outstanding Debts	3,496.82	3,763.11
Outstanding Redeemable Preference Shares	-	-
Debt Equity Ratio	1.23	(5.77)
Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued)	-	-
1. Basic	0.28	1.43
2. Diluted	0.28	1.43
Capital Redemption reserve	-	-
Debenture Redemption Reserve	1,450.00	1,450.00
Debt Service Coverage Ratio	1.12	4.10
Interest Service Coverage Ratio	1.12	5.52

for Relisys Medical Devices Ltd.,

N. L. _____
Authorised Signatory

Note :

1. Statement of Assets and Liabilities

INR in Lakhs

Particulars	As at
	30 September, 2018
	Rs
Assets	
Non-current assets	
Property, plant and equipment	2,725.47
Intangible assets	34.93
Intangible assets under development	31.83
Financial assets	-
- Investments	2,700.00
- Restricted Bank Balances	579.61
- Loans and advances	48.52
- Other financial assets	27.24
Deferred tax asset	105.14
Other non-current assets	-
	6,252.74
Current assets	
Inventories	917.25
Financial assets	
- Trade receivables	3,205.63
- Cash and Bank Balances	175.02
- Other financial assets	13.45
Other current assets	109.74
	4,421.09
Total assets	10,673.83
Equity and liabilities	
Equity	
Equity share capital	3,427.05
Other equity	(576.95)
Total equity	2,850.10
Liabilities	
Non-current liabilities	
Financial liabilities	
- Borrowings	3,418.52
- Other financial liabilities	3,543.06
Provisions	42.46
Tax Provision	11.07
Other non-current liabilities	402.14
	7,417.25
Current liabilities	
Financial liabilities	
- Trade payables	
Dues to: small and micro enterprises	5.62
: other than small and micro enterprises	34.92
- Other financial liabilities	300.80
Provisions	3.75
Other current liabilities	61.39
	406.48
Total liabilities	7,823.73
Total equity and liabilities	10,673.83

For Relisys Medical Devices Ltd.,

N. C. _____
 Authorised Signatory

- 2 The company is primarily engaged in the business of development, manufacturing and commercialization of medical devices to treat life-threatening diseases including cardiovascular, peripheral vascular, neurovascular (stroke) and structural heart disease and providing OEM services. As such, the Company operates in a single business and geographic segment in India and hence disclosing information as per the requirements of Indian Accounting Standard Operating Segments (Ind AS 108) is not applicable.
- 3 The comparative financial information are based on the previously issued standalone financial results prepared in accordance with the recognition and measurement principles of Accounting Standard 25 "Interim Financial Reporting", as specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, which have been reviewed and recommended by the Audit Committee and approved by the Board of Directors.
- 4 Assumptions to financial ratios
 - a) Debt Equity ratio = Paid up Debt capital / Equity (Net worth)
Equity (Net worth) = Equity share capital + Reserves and surplus (including capital redemption reserve + Debenture Redemption Reserve)
 - b) Debt service Coverage Ratio (DSCR) = Profit or loss before finance cost and tax expense / (finance cost + Principal repayment)
None of the debentures are due for redemption during the year and hence principal repayment amount has been considered as Nil for the computation of DSCR for the current period.
 - c) Interest Service Coverage Ration (ISCR) = Profit or loss before finance cost and tax expense / finance cost.
- 5 The above unaudited financial results for the half year ended 30th September, 2018 were subjected to a limited review by the Statutory Auditors of the company and reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 13th November, 2018.
- 6 Previous period figures have been regrouped/rearranged, wherever necessary, to conform to the classification/disclosure adopted in the current period.

FOR KENSYS Medical Devices Ltd.,


Authorized Signatory



Brahmayya & Co.,

CHARTERED ACCOUNTANTS

VIJAYAWADA, HYDERABAD, VISAKHAPATNAM, GUNTUR, KAKINADA, TANUKU, ALSO AT CHENNAI, BANGALORE AND ADONI.

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To the Board of Directors of RELISYS MEDICAL DEVICES LIMITED

We have reviewed the accompanying statement of unaudited financial results of **RELISYS MEDICAL DEVICES LIMITED** ("the company") for the half year ended September 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/IMD/DF1/ 69/2016 dated August 10, 2016.

This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. No. CIR/IMD/DF1/69/2016 dated August 10, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date : 13th November, 2018

For Brahmayya & Co.,
Chartered Accountants
Firm Registration No: 000513S




(S Satyanarayana Murthy)
Partner
Membership No: 023651

No. 7584/ITSL/OPR/18-19

November 13, 2018

To

Relisys Medical Devices Limited

Survey No.312, Pocharam Road,
Mangalpally Village, Ibrahimpatnam Mandal,
R.R Dist. - 501510, Andhra Pradesh,

Certificate for receipt and noting of information

[Pursuant to Regulation 52(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

We, IDBI Trusteeship Service Limited (“**Debenture Trustee**”) hereby confirm that we have received and noted the information, as specified under regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (“**Regulations**”), provided to us by **Relisys Medical Devices Limited** (“**the Company**”) for the financial half year ended September 2018

This Certificate is being issued pursuant to the requirements of regulation 52(5) of the aforesaid Regulations, for onward submission to Stock Exchange(s) by the Company.

for **IDBI Trusteeship Services Limited**



Authorised Signatory